Patient Support Services Contact Us

Investors

Overview

Coherus BioSciences, Inc. is a leading global biologics platform company focused on delivering high-quality biosimilar therapeutics that may expand patient access to life-changing medicines in regulated markets worldwide. In 2018, the U.S. Food and Drug Administration approved Coherus’ biosimilar UDENYCA® (pegfilgrastim-cbqv). Coherus is headquartered in the heart of California’s Silicon Valley and composed of a team of industry veterans with decades of experience pioneering biologics companies.

News
11/12/19
REDWOOD CITY, Calif. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at two upcoming investor healthcare conferences. Management will deliver a company presentation at the Jefferies 2019 London Healthcare
11/08/19
REDWOOD CITY, Calif. , Nov. 08, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective November 7, 2019 , the compensation committee of the Company’s board of directors granted options to purchase 77,000 shares of the common
11/06/19
REDWOOD CITY, Calif. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reviewed corporate highlights and reported financial results for the quarter ended September 30 , 2019.  Third Quarter 2019 Company Highlights UDENYCA®
11/06/19
Company’s First Ophthalmology Franchise Launch Pulled Forward by Two Years REDWOOD CITY, Calif. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced the Company has acquired exclusive rights from Bioeq IP AG , (“Bioeq”) a Swiss
Events & Presentations